Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John C Hunter

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Psychopharmacology|February 1, 2005
The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profilesGeoffrey B Varty, Mariagrazia Grilli, Angelo Forlani, et al.
Nature Communications|July 19, 2014
Treatment of acute lung injury by targeting MG53-mediated cell membrane repairYanlin Jia, Ken Chen, Peihui Lin, et al.
Bioorganic & Medicinal Chemistry|December 25, 2016
Structure-guided development of covalent TAK1 inhibitorsLi Tan, Deepak Gurbani, Ellen L Weisberg, et al.
European Journal of Pharmacology|May 7, 2011
The anxiolytic-like profile of the nociceptin receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octane-3-carboxamide (SCH 655842): comparison of efficacy and side effects across rodent speciesSherry X Lu, Guy A Higgins, Robert A Hodgson, et al.
Journal of Medicinal Chemistry|January 2, 2010
Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitorsYu-Sen Wang, Corey Strickland, Johannes H Voigt, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 2009
Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depressionRobert A Hodgson, Rosalia Bertorelli, Geoffrey B Varty, et al.
Journal of Medicinal Chemistry|January 2, 2010
Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validationZhaoning Zhu, Zhong-Yue Sun, Yuanzan Ye, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 15, 2011
Pharmacological characterization of a novel α2C-adrenoceptor agonist N-[3,4-dihydro-4-(1H-imidazol-4-ylmethyl)-2H-1, 4-benzoxazin-6-yl]-N-ethyl-N'-methylurea (compound A)Michel R Corboz, Maria A Rivelli, Kevin D McCormick, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Psychopharmacology|February 1, 2005
The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profilesGeoffrey B Varty, Mariagrazia Grilli, Angelo Forlani, et al.
Nature Communications|July 19, 2014
Treatment of acute lung injury by targeting MG53-mediated cell membrane repairYanlin Jia, Ken Chen, Peihui Lin, et al.
Bioorganic & Medicinal Chemistry|December 25, 2016
Structure-guided development of covalent TAK1 inhibitorsLi Tan, Deepak Gurbani, Ellen L Weisberg, et al.
European Journal of Pharmacology|May 7, 2011
The anxiolytic-like profile of the nociceptin receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octane-3-carboxamide (SCH 655842): comparison of efficacy and side effects across rodent speciesSherry X Lu, Guy A Higgins, Robert A Hodgson, et al.
Journal of Medicinal Chemistry|January 2, 2010
Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitorsYu-Sen Wang, Corey Strickland, Johannes H Voigt, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 2009
Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depressionRobert A Hodgson, Rosalia Bertorelli, Geoffrey B Varty, et al.
Journal of Medicinal Chemistry|January 2, 2010
Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validationZhaoning Zhu, Zhong-Yue Sun, Yuanzan Ye, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 15, 2011
Pharmacological characterization of a novel α2C-adrenoceptor agonist N-[3,4-dihydro-4-(1H-imidazol-4-ylmethyl)-2H-1, 4-benzoxazin-6-yl]-N-ethyl-N'-methylurea (compound A)Michel R Corboz, Maria A Rivelli, Kevin D McCormick, et al.
Pageof 6